Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.80
-$0.07(-1.37%)
At close: 4:00 PM EST
$1.80
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.07 - $6.18
Previous CloseN/A
Volume102.94K
Average Volume (3M)5.24M
Market Cap
$101.34M
Enterprise Value-$49.49T
Total Cash (Recent Filing)$65.00T
Total Debt (Recent Filing)$15.51T
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume1,755,229
30 Day Avg. Volume5,243,970
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-488.35K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit383.99M
Enterprise Value/Ebitda1.92M
Forecast
1Y Price Target
$5.50Price Target Upside205.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$27.12M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsSeveral trials reported treatment effects and pooled analyses could build a compelling efficacy case for the drug in reducing signs and symptoms of dry eye disease.
Controlled Chamber StudyA chamber study conducted in highly controlled conditions demonstrated meaningful benefit on ocular discomfort, helping address variability seen in conventional dry eye trials.
Partnership And Commercialization RightsAn outstanding option agreement with AbbVie grants US development and commercialization rights, creating a clear pathway for strategic partnership or acquisition that could accelerate market access.
Bears Say
Competitive Market DynamicsA crowded dry eye treatment market with multiple prescription drugs and many over-the-counter options could restrict market penetration even if regulatory approval is obtained.
Complete Response LetterThe FDA issued a Complete Response Letter indicating the application lacks substantial evidence from adequate and well-controlled studies to show the drug works as represented, posing a significant approval hurdle.
Regulatory Inconsistency ConcernsFDA reviewers flagged inconsistent study results that weaken the reliability and meaningfulness of positive findings across trials, raising regulatory uncertainty.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $6.17 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $101.34M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Jul 31, 2026 which is in 76 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.057 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.011.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,321,068 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.057 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (205.56% Upside)
$5.50 (205.56% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $105.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.80%
12-Months-Change
Fundamentals
Return on Equity
-32.76%
Trailing 12-Months
Asset Growth
-28.66%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$5.50
▲(205.56% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.28% Insiders
8.76% Mutual Funds
2.60% Other Institutional Investors
76.30% Public Companies and
Individual Investors